Clinical trial
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or…
NCT00248560 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00248560 |
|---|---|
| Title | Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer |
| Official title | Phase II Study of Gemcitabine and Docetaxel (GEMDOC) Combination in Patients With Previously Treated Recurrent or Metatstatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, Gemcitabine |
| Enrollment | 36 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Jun 1, 2012 |
| First posted | Nov 4, 2005 |
| Last update posted | Mar 5, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: